West Pharmaceutical Services Statistics

Share Statistics

West Pharmaceutical Services has 71.85M shares outstanding. The number of shares has increased by -0.76% in one year.

Shares Outstanding Shares Outstanding n/a Close	71.85M
Shares Change (YoY) Shares Change (YoY) n/a Close	-0.76%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	-0.18%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	95.79%
Shares Floating Shares Floating n/a Close	71.39M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	39
FTD / Avg. Volume FTD / Avg. Volume n/a Close	n/a

Short Selling Information

The latest short interest is 2.13M, so 2.97% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	2.13M
Short % of Shares Out Short % of Shares Out n/a Close	2.97%
Short % of Float Short % of Float n/a Close	3.91%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	3.88

Valuation Ratios

The PE ratio is 48.53 and the forward PE ratio is 31.21. West Pharmaceutical Services's PEG ratio is -3.13.

PE Ratio PE Ratio n/a Close	48.53
Forward PE Forward PE n/a Close	31.21
PS Ratio PS Ratio n/a Close	8.26
Forward PS Forward PS n/a Close	4.4
PB Ratio PB Ratio n/a Close	8.91
P/FCF Ratio P/FCF Ratio n/a Close	86.51
PEG Ratio PEG Ratio n/a Close	-3.13

Financial Ratio History

Enterprise Valuation

West Pharmaceutical Services has an Enterprise Value (EV) of 23.73B.

EV / Sales EV / Sales n/a Close	8.2
EV / EBITDA EV / EBITDA n/a Close	31.9
EV / EBIT EV / EBIT n/a Close	36.32
EV / FCF EV / FCF n/a Close	85.85

Financial Position

The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.11.

Current Ratio Current Ratio n/a Close	2.79
Quick Ratio Quick Ratio n/a Close	2.11
Debt / Equity Debt / Equity n/a Close	0.11
Debt / EBITDA Debt / EBITDA n/a Close	0.41
Debt / FCF Debt / FCF n/a Close	1.09
Interest Coverage Interest Coverage n/a Close	189.97

Financial Efficiency

Return on Equity is 18.37% and Return on Invested Capital is 14.98%.

Return on Equity Return on Equity n/a Close	18.37%
Return on Assets Return on Assets n/a Close	13.52%
Return on Invested Capital Return on Invested Capital n/a Close	14.98%
Revenue Per Employee Revenue Per Employee n/a Close	$272,943.4
Profits Per Employee Profits Per Employee n/a Close	$46,481.13
Employee Count Employee Count n/a Close	10,600
Asset Turnover Asset Turnover n/a Close	0.79
Inventory Turnover Inventory Turnover n/a Close	5.03

Taxes

Income Tax Income Tax n/a Close	107.5M
Effective Tax Rate Effective Tax Rate n/a Close	18.36%

Stock Price Statistics

The stock price has increased by -33.32% in the last 52 weeks. The beta is 1.09, so West Pharmaceutical Services's price volatility has been higher than the market average.

Beta Beta n/a Close	1.09
52-Week Price Change 52-Week Price Change n/a Close	-33.32%
50-Day Moving Average 50-Day Moving Average n/a Close	212.47
200-Day Moving Average 200-Day Moving Average n/a Close	274.81
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	58.77
Average Volume (20 Days) Average Volume (20 Days) n/a Close	831,782

Income Statement

In the last 12 months, West Pharmaceutical Services had revenue of 2.89B and earned 492.7M in profits. Earnings per share was 6.75.

Revenue Revenue n/a Close	2.89B
Gross Profit Gross Profit n/a Close	998.5M
Operating Income Operating Income n/a Close	569.9M
Net Income Net Income n/a Close	492.7M
EBITDA EBITDA n/a Close	743.8M
EBIT EBIT n/a Close	588.5M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	6.75

Full Income Statement

Balance Sheet

The company has 484.6M in cash and 302.3M in debt, giving a net cash position of 182.3M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	484.6M
Total Debt Total Debt n/a Close	302.3M
Net Cash Net Cash n/a Close	182.3M
Retained Earnings Retained Earnings n/a Close	3.96B
Total Assets Total Assets n/a Close	3.62B
Working Capital Working Capital n/a Close	930.8M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 653.4M and capital expenditures -377M, giving a free cash flow of 276.4M.

Operating Cash Flow Operating Cash Flow n/a Close	653.4M
Capital Expenditures Capital Expenditures n/a Close	-377M
Free Cash Flow Free Cash Flow n/a Close	276.4M
FCF Per Share FCF Per Share n/a Close	3.79

Full Cash Flow Statement

Margins

Gross margin is 34.51%, with operating and profit margins of 19.7% and 17.03%.

Gross Margin Gross Margin n/a Close	34.51%
Operating Margin Operating Margin n/a Close	19.7%
Pretax Margin Pretax Margin n/a Close	20.24%
Profit Margin Profit Margin n/a Close	17.03%
EBITDA Margin EBITDA Margin n/a Close	25.71%
EBIT Margin EBIT Margin n/a Close	19.7%
FCF Margin FCF Margin n/a Close	9.55%

Dividends & Yields

WST pays an annual dividend of $1.04, which amounts to a dividend yield of 0.38%.

Dividend Per Share Dividend Per Share n/a Close	$1.04
Dividend Yield Dividend Yield n/a Close	0.38%
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	5%
Payout Ratio Payout Ratio n/a Close	16.3%
Earnings Yield Earnings Yield n/a Close	2.06%
FCF Yield FCF Yield n/a Close	1.16%

Dividend Details

Analyst Forecast

The average price target for WST is $355, which is 58.4% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$355
Price Target Difference Price Target Difference n/a Close	58.4%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	$51.3
Lynch Upside Lynch Upside n/a Close	-77.11%
Graham Number Graham Number n/a Close	74.7
Graham Upside Graham Upside n/a Close	-66.67%

Stock Splits

The last stock split was on Sep 27, 2013. It was a forward split with a ratio of 2:1.

Last Split Date Last Split Date n/a Close	Sep 27, 2013
Split Type Split Type n/a Close	forward
Split Ratio Split Ratio n/a Close	2:1

Scores

Altman Z-Score Altman Z-Score n/a Close	12.89
Piotroski F-Score Piotroski F-Score n/a Close	8

West Pharmaceutical Servi... (WST)